SPY001 Phase 2 SKYLINE Trial Achieves Primary Endpoint with Positive Ulcerative Colitis Data, Advancing Combination Cohorts

summarizeSummary

Spyre Therapeutics reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001 in ulcerative colitis, meeting the primary endpoint and showing strong secondary efficacy with a favorable safety profile.

check_boxKey Events

• SPY001 Phase 2 Data Positive

  Spyre Therapeutics announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for moderate-to-severely active ulcerative colitis.

• Primary Endpoint Met

  SPY001 achieved the primary endpoint, demonstrating a statistically significant reduction in the Robarts Histopathology Index (RHI) score of 9.2 points (p<0.0001).

• Strong Secondary Efficacy

  Key secondary endpoints showed clinically meaningful rates of clinical remission (40%) and endoscopic improvement (51%).

• Favorable Safety Profile

  SPY001 was well tolerated with a safety profile consistent with the α4β7 class; one serious adverse event was deemed not drug-related.

auto_awesomeAnalysis

Spyre Therapeutics announced highly positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001 in moderate-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant reduction in the Robarts Histopathology Index (RHI) score and demonstrated clinically meaningful rates for key secondary endpoints like clinical remission and endoscopic improvement. The favorable safety profile, consistent with its class, further de-risks the asset. This strong clinical validation for SPY001, especially as the company progresses to Part B of the trial to evaluate combination therapies, is a significant catalyst for a life sciences company, reinforcing its pipeline and potential market position. This news provides strong fundamental support for the stock, which is currently trading near its 52-week high.